EUnetHTA submits Position to EMA Public Consultation
EUnetHTA has submitted a position as a response to the public consultation on the EMA draft policy on the publication and access to clinical trial data. The following EUnetHTA organisations explicitly supported the EUnetHTA position: Hauptverband der Österreichishen Sozialversicherungsträger, HVB, Austria Gesundheit Österreich GmbH/Geschäftsbereich BIQG/GÖG, Austria Ludwig Boltzmann Institut für Health Technology Assessment, LBI, Austria […]
Co-chair function in the EUnetHTA Stakeholder Forum
The EUnetHTA Executive Committee and Stakeholder Forum have agreed to introduce a co-chair function to strengthen engagement of the four stakeholder groups represented in the Stakeholder Forum, ie, providers, patients/consumers, payers and industry. The co-chair will be supported by a co-chair team consisting of representatives of all four Stakeholder Forum Groups (Providers, Patients/Consumers, Payers and […]
Concept paper on Osteoarthritis available
The concept paper on Osteoarthritis “EunetHTA guideline on data requirements for the assessment of health technologies used for the treatment of osteoarthritis of the hip and knee” is available. We are pleased to announce the publication of the concept paper on Osteoarthritis a “EunetHTA guideline on data requirements for the assessment of health technologies used for […]
JA1 Final Technical Report available
The Final technical report on the implementation of the EUnetHTA JA1 (2010-2012) is now available. The report provides the details on the activities undertaken, results achieved and recommendations for the next steps in the development of the European cooperation on HTA. Please find the report here.
Pilot of Rapid Assessment on ‘Zostavax for the prevention herpes zoster’ available
The first pilot of rapid assessment of WP5 JA2 Strand A on ‘Zostavax for the prevention herpes zoster’ is now available. We are pleased to announce the publication of the first pilot rapid assessment of WP5 JA2 Strand A. This pilot rapid assessment evaluates the herpes zoster vaccine ‘Zostavax’ and its prevention of herpes zoster […]
The first pilot rapid assessment of WP5 JA2 Strand B on “Duodenal-jejunal bypass sleeve” is now available
We are pleased to announce that the first pilot rapid assessment of WP5 JA2 Strand B on “Duodenal-jejunal bypass sleeve for the treatment of obesity with or without Type II Diabetes Mellitus” is available. This pilot rapid assessment evaluates the duodenal-jejunal bypass sleeve which has been introduced as an alternative for the treatment of obesity […]
EUnetHTA-EFPIA Collaboration
EUnetHTA and EFPIA are pleased to announce their Framework for a joint EUnetHTA-EFPIA Advisory Working Group. The Framework will facilitate the involvement of pharmaceutical companies in the pilot work of EUnetHTA JA2. Please find the Framework here.
New Terms of Use for the HTA Core Model
WP8 has produced a new version 1.1 of the Terms of Use (ToU) for the HTA Core Model. It is based on the new Policy for the HTA Core Model and core HTA information recently approved by the Executive Committee. The ToU is a more conscise document and contains only key principles relevant to HTA […]
Response to PC on WP5 Strand B Draft Project Plan available
The author’s replies to the public consultation of the Draft Project Plan on “Renal sympathetic denervation (Symplicity®) for the treatment of resistant arterial hypertension” is now available. The public consultation took place between 28 May and 12 June, 2013. The closed call for public consultation can be found here here. The response to the public consultation can be found here.
Minutes from all Stakeholder Forum meetings are available
Please find below a list of minutes from the previous Stakeholder Forum meetings Summary of the SF e-meeting, 8 September 2015 Summary report of the SF e-meeting, 12 May 2015 Summary report of the SF face-to-face meeting, 26 February 2015 Summary report of the SF e-meeting, 18 November 2014 Summary report of the SF e-meeting, […]
